Relapsed/Refractory Multiple Myeloma (RRMM) research hub
3 indexed studies · 2 currently recruiting
- recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
This study looks at how well new treatments called teclistamab and talquetamab work for people in the UK with a specific type of blood cancer called multiple myeloma, when these treatments are given outside of formal clinical trials. It's about understanding real-world results.
Denmark · France · Germany - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma
This study looks at a new medicine called HPN217 for people with multiple myeloma that has come back or isn't responding to treatment. It's the first time this medicine is being given to people, and doctors want to see if it's safe, what dose works best, and how the body handles it.
Spain · France - recruitingPHASE3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is testing a new drug, linvoseltamab, for multiple myeloma that has returned or needs re-treatment. It compares linvoseltamab to a standard three-drug combination (elotuzumab, pomalidomide, and dexamethasone) to see which works better and has fewer side effects.
United States · Australia · Belgium